The US Food and Drug Administration and National Institutes of Health are working together on two separate projects that aim to advance novel treatments, the FDA has recently announced.
The first project, the Critical Path for Rare Neurodegenerative Diseases (CP-RND), is a public-private partnership to develop better understanding of and more effective treatments for diseases such as amyotrophic lateral sclerosis (ALS)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?